How can ‘Hy's law’ help the clinician?

descriptionPublicationkeyboard_double_arrow_right Article 22 Mar 2006 English Publisher:WileyJournal:Pharmacoepidemiology and Drug Safety, volume 15, pages 235-239 (issn: 1053-8569, eissn: 1099-1557,

Copyright policy )

Authors: Senior, John R.;

doi: 10.1002/pds.1210

pmid: 16552792

How can ‘Hy's law’ help the clinician?

- Summary
- Subjects
- Metrics

Abstract

n/a

Related Organizations

Center for Drug Evaluation and Research
United States
United States Food and Drug Administration
United States

Keywords

Benzylamines, Anti-Inflammatory Agents, Non-Steroidal, Anticoagulants, Alanine Transaminase, Bilirubin, Risk Assessment, Benzophenones, Liver, Predictive Value of Tests, Adverse Drug Reaction Reporting Systems, Azetidines, Humans, Hypoglycemic Agents, Thiazolidinediones, Chemical and Drug Induced Liver Injury, Chromans, Drug Approval, Biomarkers, Bromobenzenes, Randomized Controlled Trials as Topic

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	46
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Top 10%
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Top 10%
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Top 10%